PNeoVCA
Phase 1/2 Recruiting
132 enrolled
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
Phase 1 Completed
66 enrolled
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Phase 1 Completed
13 enrolled 11 charts
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Phase 1 Completed
18 enrolled
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase 1 Completed
7 enrolled
HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer
Phase 1 Completed
60 enrolled
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
Phase 1 Completed
Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy
Phase 2 Completed
21 enrolled 12 charts
GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer
Phase 2 Completed
72 enrolled 8 charts
Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
Phase 1 Withdrawn
Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer
Phase 1 Completed
9 enrolled 7 charts
Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer
Phase 2 Completed
59 enrolled 5 charts
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
Phase 2 Completed
20 enrolled